| pubmed-article:19745032 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C0001699 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C0025064 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C0597979 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C1314792 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C1120106 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:19745032 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:19745032 | pubmed:issue | Pt 1 | lld:pubmed |
| pubmed-article:19745032 | pubmed:dateCreated | 2009-12-16 | lld:pubmed |
| pubmed-article:19745032 | pubmed:abstractText | The aim was to study the clinical and microbiological features associated with a carbapenem-resistant Klebsiella pneumoniae isolate that had been selected in vivo by an ertapenem-containing regimen in a patient with mediastinitis despite high blood and mediastinal levels of ertapenem. Carbapenem resistance was characterized by conjugation, PCR, DNA sequencing and analysis of outer-membrane proteins. The isolates susceptible and resistant to the carbapenems were compared by ribotyping and PFGE. Resistance to all available beta-lactams was most probably due to combined production of extended-spectrum beta-lactamase (ESBL) CTX-M-15 and loss of OmpK36 porin. The results of ribotyping and PFGE suggest that the carbapenem-resistant strain was a derivative of the original mediastinal isolate rather than a superinfecting isolate. This observation stresses the risk of selection of pan-penem resistant strains of enterobacteria when ertapenem is used for the treatment of severe infections due to ESBL-producing enterobacteria. | lld:pubmed |
| pubmed-article:19745032 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19745032 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19745032 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19745032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19745032 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19745032 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19745032 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19745032 | pubmed:issn | 1473-5644 | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:AndremontAnto... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:LasockiSigism... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:Muller-Seriey... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:MontraversPhi... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:CourvalinPatr... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:SkurnikDavidD | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:KitzisMarie... | lld:pubmed |
| pubmed-article:19745032 | pubmed:author | pubmed-author:BremontSylvie... | lld:pubmed |
| pubmed-article:19745032 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19745032 | pubmed:volume | 59 | lld:pubmed |
| pubmed-article:19745032 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19745032 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19745032 | pubmed:pagination | 115-9 | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:meshHeading | pubmed-meshheading:19745032... | lld:pubmed |
| pubmed-article:19745032 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19745032 | pubmed:articleTitle | Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. | lld:pubmed |
| pubmed-article:19745032 | pubmed:affiliation | Laboratoire de Bactériologie, Hôpital Bichat-Claude Bernard APHP, Université Paris VII, Paris Cedex 18, France. david.skurnik@bch.aphp.fr | lld:pubmed |
| pubmed-article:19745032 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19745032 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:19745032 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
